IDYA IDEAYA Biosciences, Inc.
Healthcare$29.10-1.49%ClosedMarket Cap: $2.56B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.75
P/S
11.35
EV/EBITDA
-13.57
DCF Value
$-121.93
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.5%
Operating Margin
-81.4%
Net Margin
-62.2%
ROE
-14.0%
ROA
-13.6%
ROIC
-19.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.6M | 82.6% | $-108.5M | $-98.5M | $— | — |
| Q4 null | $10.9M | 100.0% | $-94.6M | $-83.3M | $— | — |
| FY null | $218.7M | 97.9% | $-159.3M | $-113.7M | $— | — |
| Q3 null | $207.8M | 100.0% | $108.5M | $119.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-88.8M | $-77.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-84.4M | $-71.4M | $— | — |
| Q4 null | $7.0M | 90.8% | $-144.1M | $-130.3M | $— | — |
| FY null | $7.0M | 45.2% | $-327.0M | $-274.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-66.9M | $-51.8M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-64.9M | $-52.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-51.0M | $-39.6M | $— | — |
| Q4 2023 | $3.9M | 73.9% | $-41.9M | $-34.0M | $-0.52 | — |